Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery

Martín‐Escolano, Rubén; Rosales, María J.; Marín, Clotilde

doi:10.1016/j.actatropica.2022.106679

Cited by 2 publications

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD affects around 6 to 8 million people worldwide, causing 14,000 to 50,000 deaths annually. Additionally, recent estimates suggest that almost 70 to 100 million people are at risk of infection [42].…”

Section: -Nitroimidazole Derivatives Against American Trypanosomiasismentioning

confidence: 99%

Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review

Vichi-Ramírez,

López-López,

Soriano-Correa

et al. 2024

Future Pharmacology

View full text Add to dashboard Cite

Neglected tropical diseases (NTDs) are a significant global health problem. Additionally, anti-protozoan treatments are toxic, and their therapeutic regimens require prolonged treatment times and high concentrations of the drugs. Additionally, multi-resistant protozoan strains represent an important global emergency that must be addressed. For these reasons, global efforts are being made to identify new drug candidates that are capable of combating these kinds of diseases. This systematic review shows that 5-nitroimidazole derivatives have been successfully used against neglected tropical protozoan diseases (NTPDs), with a specific focus on three diseases: malaria, leishmaniasis, and human trypanosomiasis. Some nitroimidazole derivatives have been repurposed, and an important group of new drugs is available for the treatment of NTPDs. Finally, we address 5-nitroimidazoles using chemoinformatics and medicinal chemistry tools to describe the most recent and promising 5-nitroimidazole derivatives associated with anti-protozoal activity using their published in vitro and in vivo data. We show that 5-nitroimidazoles offer a broader spectrum of activity against a variety of protozoal pathogens. More importantly, these compounds demonstrate a significantly reduced systemic toxicity compared to other nitroimidazoles. This makes them a more favorable option in the treatment of protozoal infections, particularly in scenarios where the patient’s tolerance to drug side effects is a critical concern.

show abstract

Section: -Nitroimidazole Derivatives Against American Trypanosomiasismentioning

confidence: 99%

Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review

Vichi-Ramírez,

López-López,

Soriano-Correa

et al. 2024

Future Pharmacology

View full text Add to dashboard Cite

show abstract

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

Torchelsen,

Mazzeti,

Mosqueira

2024

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery

Cited by 2 publications

References 85 publications

Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review

Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

Contact Info

Product

Resources

About